CS
PACB icon

Candriam SCA’s Pacific Biosciences PACB Stock Holding History

Candriam SCA’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-280,431
Closed -$7.17M – 850
2021
Q3 		$7.17M Hold
280,431
– – 0.05% 329
2021
Q2 		$9.81M Buy
+280,431
New +$8.16M 0.07% 288
2020
Q2 		– Sell
-411,991
Closed -$2.07M – 848
2020
Q1 		$2.07M Hold
411,991
– – 0.02% 519
2019
Q4 		$2.12M Buy
411,991
+80,636
+24% +$410K 0.02% 534
2019
Q3 		$1.71M Sell
331,355
-2,000
-0.6% -$11.2K 0.02% 524
2019
Q2 		$3.89M Buy
333,355
+2,000
+0.6% +$14K 0.05% 385
2019
Q1 		$2.4M Buy
331,355
+44,000
+15% +$318K 0.03% 458
2018
Q4 		$2.13M Buy
+287,355
New +$1.82M 0.03% 446

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Candriam SCA's PACB Position: Q4 2021 in Review

Candriam SCA sold out of Pacific Biosciences (PACB) in Q4 2021, closing a stake of 280,431 shares — an estimated $7.17M sold.

Candriam SCA first reported a position in PACB in Q4 2018 and held it in 8 quarters. The position peaked at $9.81M in Q2 2021. 255 funds tracked by Wall St. Rank hold PACB as of Q4 2021.

  • Candriam SCA reported no remaining Pacific Biosciences position as of Q4 2021 after selling out during the quarter.
  • Candriam SCA sold 280,431 Pacific Biosciences shares in Q4 2021, an estimated $7.17M.
  • Candriam SCA first reported a position in Pacific Biosciences in Q4 2018 and held it in 8 quarters.
  • Candriam SCA's Pacific Biosciences position peaked at $9.81M in Q2 2021.
  • 255 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2021.

Based on Candriam SCA's 13F filing for Q4 2021, filed 10 Feb 2022.